Hepion Pharmaceuticals, Inc. (HEPA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US4268971045
Hepion Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -4.16 m USD |
| EBIT | -8.28 m USD |
| Net income | -8.28 m USD |
| Diluted EPS – continuing operations | -0.88 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
More stocks
- EON Resources Inc. (EONR)
- Seres Therapeutics, Inc. (MCRB)
- DarioHealth Corp. (DRIO)
- Norris Industries, Inc. (NRIS)
- Galenfeha, Inc. (NGHI)
- PACIFIC HEALTH CARE ORGANIZATION INC (PFHO)
- Bionano Genomics, Inc. (BNGO)
- SunPower Inc. (SPWR)
- KYNTRA BIO, INC. (KYNB)
- Inhibitor Therapeutics, Inc. (INTI)
- Neuphoria Therapeutics Inc. (NEUP)
- KEEMO Fashion Group Ltd (KMFG)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.